Kybella®

• Submental fullness, sometimes referred to as “double chin,” is a common, yet undertreated facial aesthetic condition.¹It can detract from an otherwise balanced and harmonious facial appearance² – leading to an older and heavier look.³
• Submental fullness can impact a broad range of adults, including both women and men, and can be caused by aging, genetics and weight gain.⁴
• According to a 2015 survey by the American Society for Dermatologic Surgery (ASDS), over 2/3 of consumers are bothered by submental fullness – nearly as many as those bothered by lines and wrinkles around the eyes.⁵

How does Kybella work?

• KYBELLA^®is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat.⁷
• When injected into subcutaneous fat, KYBELLA^®causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After the aesthetic response is achieved, retreatment with KYBELLA^® is not expected.¹
• To avoid potential tissue damage, KYBELLA^®should not be injected into or in close proximity (1-1.5 cm) to the marginal mandibular nerve, salivary glands, lymph nodes and muscles.

What are the results of Kybella?

• 68.2% of subjects treated with KYBELLA^®experienced a ≥1-grade improvement with KYBELLA^® compared to 20.5% of placebo-treated subjects, based upon validated physician and patient measurements.*
• 16% of patients experienced a ≥2-grade improvement with KYBELLA^®, compared to 2% of patients who responded to placebo, based on validated physician and patient measurements
• KYBELLA^®treatment resulted in high patient satisfaction – 79% of KYBELLA^®-treated patients reported satisfaction with their appearance in association with their face and chin.
• Patients also reported improvement in the visual and emotional impact of submental fat when asked how happy, bothered, self-conscious, embarrassed, old and overweight they felt following treatment in relation to the amount of their submental fat.
• Marginal mandibular nerve (MMN) injury occurred in 4% and dysphagia occurred in 2% of subjects. To avoid potential tissue damage, KYBELLA^®should not be injected into or in close proximity (1-1.5 cm) to the MMN, salivary glands, lymph nodes and muscles.
• The most common adverse reactions were edema/swelling, hematoma/bruising, pain, numbness, erythema and induration.

*Information provided by https://hcp.mykybella.com/